Multiple System Atrophy Market: Current Analysis and Forecast (2023-2030)

Multiple system atrophy is a very rare neurodegenerative disorder of nervous system where nerve cells or brain cells go through a gradual damage. It affects all activities controlled by brain and severely impacts movement, balance and autonomous nervous system. Currently, there is no specific diagnosis test or treatment available in the market for the identification or management of multiple system atrophy. This is one of the major factor driving the market during the forecast period. Several other factors, increase in geriatric population, including government initiatives for research and development activities, promising product pipeline and technological advancements are driving the growth of the market during the forecast period.

The Multiple System Atrophy Market is expected to grow at a strong CAGR of 4% during the forecast period owing to increase in geriatric population, as this disorder is more prevalent in age 50-55 years and above. Rising geriatric population is a propelling factor in Multiple System Atrophy market globally. According to World Health Organization (WHO), share of people aged above 60 will raise to 1.4 billion by 2030 while this share will increase to 2.1 billion by 2050 which would be more than double of the share of geriatric population in year 2020 i.e., 1 billion. China and India are leading in the list of countries with highest geriatric population in the world.

Based on the types, the market is bifurcated into parkinsonian and cerebellar. The cerebellar held dominant share of the market in 2022. MSA-C (cerebellar) is identified with cerebellar ataxia. MSA-C exhibits slower progression of the disease and patients survive relatively a longer life span as compared to MSA-P. The incidence and prevalence of MSA-C is 3.4 to 4.9 cases per 100,000 population as estimated in the year 2020. Thus, the increase in the prevalence of cerebellar subtype is one of the major factor driving the segment growth.

By diagnosis, the market is categorized into magnetic resonance imaging (MRI), positron emission tomography (PET), single photon emission computed tomography (SPECT), tilt table test and others. Positron emisssion tomography (PET) has shown more prevalence over the market in recent years than other diagnostic methods. PET diagnostics can be used to monitor metabolic functions in particular part of brain. PET scan dominated Multiple System Atrophy market in year 2023. For instance, in October 2020, Siemens launched a new PET scanner, named Biograph Vision Quadra, with a 106-cm axial PET field of view which facilitates whole-body imaging.

Based on age, the market is differentiated into Pediatric, Adults and Geriatric. Multiple system atrophy has shown prevalence in people aged 50-55 and above. The rising geriatric population has turned out to be a driving factor in the market. The geriatric population is expected to rise considerably in the forecast period. WHO reports suggest that the geriatric population is expected to double (2.1 billion) in year 2050 as compared to the geriatric population (1 billion) in year 2020.

Based on end use, the market is segmented into hospitals, ambulatory surgical centers and others. The hospitals held the significant share in the Multiple System Atrophy Market in 2022. This is due to higher diagnostic tests of multiple system atrophy in hospitals as most diagnostic equipments are available in hospital settings. Apart from this, the growing number of hospitals is also propelling the segmental growth. For instance, according to the American Hospital Association, there were about 6,093 hospitals in the U.S. in October 2022, of which comprises community hospitals run by non-profit organizations as well as by state and local governments.

For a better understanding of the market adoption of the dental clensing tablet industry, the market is analyzed based on its worldwide presence in the countries such as North America (U.S., Canada, Rest of North America), Europe (Germany, U.K., France, Spain, Italy, Rest of Europe), Asia-Pacific (China, Japan, India, Rest of Asia-Pacific), Rest of World. North America has reported highest market share in multiple system atrophy market in the year 2022 owing to rising neurogenetic disorders in the country. Multiple system atrophy is anticipated to grow at a substantial CAGR during the forecast period. According to National Institute of Neurological Disorders and Stroke, it affects significantly 15,000 to 50,000 americans irrespective of colour or racial groups. Further, the rise in research and development activities in the country is also driving the market growth during the forecast period. Over the projection period, this is expected to increase demand for multiple system atrophy treatment in this region. For instance, recently in May,2023, Alterity Therapeutics consucted Phase 2 trials for drug ATH434 against multiple system atrophy in U.S.

Some of the major players operating in the market include: Biohaven, Ltd.; Theravance Biopharma; Sumitomo Dainippon Pharma Co., Ltd.; Alterity Therapeutics; AstraZeneca; Biogen; Merck & Co., Inc.; Neuropore Therapies, Inc.; WaveBreak Therapeutics; Newron Pharmaceuticals SPA.